Velleja Research, Milan, Italy.
Probiotical Research Srl, Novara, Italy.
Clin Nutr ESPEN. 2021 Apr;42:15-21. doi: 10.1016/j.clnesp.2020.12.025. Epub 2021 Feb 17.
BACKGROUNDS & AIMS: Strains belonging to bifidobacteria have been documented as being helpful in adults with intestinal dysbiosis conditions, like those related to irritable bowel syndrome (IBS). This review aims to present the most relevant evidence regarding the efficacy of Bifidobacterium longum W11, a Bifidobacterium used in clinical settings for conditions such as IBS and inflammatory bowel disease.
The following electronic databases were systematically searched up to August 2020: MEDLINE (via PubMed), EMBASE, Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and Clinicaltrials.gov.
Data arising from pooled analysis, 7 in vitro/pharmacological studies, 7 clinical trials including 1 randomized, double-blind and placebo-controlled, showed that the probiotic strain B. longum W11 has been extensively studied for its efficacy in subjects with IBS with constipation, leading to a significant reduction in symptoms. In particular, its role in alleviating constipation was also confirmed in subjects for whom a low-calorie weight-loss diet led to the slowing down of gut motility. The probiotic characteristics of B. longum W11 were further demonstrated in the treatment of minimal hepatic encephalopathy and hepatic disease. The most remarkable trait of B. longum W11 is its non-transmissible antibiotic resistance, due to a nucleotide polymorphism mutation in the rpoB gene, making it resistant to antibiotics of the rifampicin group, including rifaximin. The co-administration of B. longum W11 and rifaximin in patients with symptomatic uncomplicated diverticular disease brought about a further significant improvement in the clinical condition compared to patients treated with rifaximin alone. B. longum W11 is a probiotic which could synergize with rifaximin as an adjuvant to antibiotic treatment.
Taken altogether these findings demonstrate the clinical role of the strain W11 both in some functional and in some inflammatory bowel diseases.
双歧杆菌菌株已被证明对患有肠道菌群失调的成年人有益，例如与肠易激综合征（IBS）相关的那些。本综述旨在介绍双歧杆菌 longum W11 的最相关证据，双歧杆菌 longum W11 被用于临床 IBS 和炎症性肠病等疾病。
系统检索了截至 2020 年 8 月的以下电子数据库：MEDLINE（通过 PubMed）、EMBASE、Cochrane 对照试验中心数据库（通过 CENTRAL）、Google Scholar 和 Clinicaltrials.gov。
汇总分析、7 项体外/药理学研究和 7 项临床试验的数据表明，益生菌菌株 B. longum W11 已广泛研究其在便秘型 IBS 患者中的疗效，可显著减轻症状。特别是，在因低热量减肥饮食导致肠道蠕动减慢的患者中，也证实了其在缓解便秘方面的作用。B. longum W11 的益生菌特性在治疗轻微肝性脑病和肝脏疾病中也得到了进一步证实。B. longum W11 最显著的特征是其非可传播的抗生素耐药性，这是由于 rpoB 基因突变导致其对包括利福昔明在内的利福霉素类抗生素具有耐药性。B. longum W11 与利福昔明联合应用于有症状的单纯性憩室病患者，与单独应用利福昔明相比，可进一步显著改善临床状况。B. longum W11 是一种益生菌，可与利福昔明协同作为抗生素治疗的辅助药物。
综上所述，这些发现证明了 W11 菌株在某些功能性和炎症性肠病中的临床作用。
